@article {Bettiol2020.11.09.20228197, author = {Alessandra Bettiol and Renato Alberto Sinico and Franco Schiavon and Sara Monti and Enrica Paola Bozzolo and Franco Franceschini and Marcello Govoni and Claudio Lunardi and Giuseppe Guida and Giuseppe Lopalco and Giuseppe Paolazzi and Angelo Vacca and Gina Gregorini and Pietro Leccese and Matteo Piga and Fabrizio Conti and Paolo Fraticelli and Luca Quartuccio and Federico Alberici and Carlo Salvarani and Silvano Bettio and Simone Negrini and Carlo Selmi and Savino Sciascia and Gabriella Moroni and Loredana Colla and Carlo Manno and Maria Letizia Urban and Alfredo Vannacci and Maria Rosa Pozzi and Paolo Fabbrini and Stefano Polti and Mara Felicetti and Maria Rita Marchi and Roberto Padoan and Paolo Delvino and Roberto Caporali and Carlomaurizio Montecucco and Lorenzo Dagna and Adriana Cariddi and Paola Toniati and Silvia Tamanini and Federica Furini and Alessandra Bortoluzzi and Elisa Tinazzi and Lorenzo Delfino and Iuliana Badiu and Giovanni Rolla and Vincenzo Venerito and Florenzo Iannone and Alvise Berti and Roberto Bortolotti and Vito Racanelli and Guido Jeannin and Angela Padula and Alberto Cauli and Roberta Priori and Armando Gabrielli and Milena Bond and Martina Tedesco and Giulia Pazzola and Paola Tomietto and Marco Pellecchio and Chiara Marvisi and Federica Maritati and Alessandra Palmisano and Christian Dejaco and Johann Willeit and Stefan Kiechl and Iacopo Olivotto and Peter Willeit and Domenico Prisco and Augusto Vaglio and Giacomo Emmi and on behalf of the Italian EGPA Consortium}, title = {Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome)}, elocation-id = {2020.11.09.20228197}, year = {2021}, doi = {10.1101/2020.11.09.20228197}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background and objective Systemic small vessel vasculitides carry an increased risk of acute arterial and venous thromboembolic events (AVTE); however, this risk has not been systematically explored in Eosinophilic Granulomatosis with Polyangiitis (EGPA). This study assessed the occurrence and main risk factors of AVTE among EGPA patients as compared to the general community from the population-based Bruneck cohort.Methods We conducted a retrospective multicenter cohort study on 573 EGPA patients. Clinical and serological data were collected at diagnosis. Occurrence of AVTE and time to the first AVTE after EGPA diagnosis were recorded. Age-standardized event rate (SER) of AVTE as compared to the reference cohort was assessed. Cox regression was applied to identify AVTE predictors.Results 129 EGPA patients (22.5\%) had AVTE, considered as potentially life-threatening in 55.8\%. Seventy patients experienced an AVTE prior to diagnosis (of whom 58.6\% in the two years before diagnosis) and 75 following EGPA diagnosis, of whom 56\% in the two subsequent years. The SER of AVTE as compared to the reference cohort was 2.10 (95\% CI 1.67-2.63). This risk was particularly increased in patients with history of AVTE and with a Birmingham Vasculitis Activity Score >=20 at diagnosis. Patients receiving immunosuppression within 2 months of diagnosis were at lower risk, while antiplatelet or anticoagulant treatment did not confer measurable benefit.Conclusion EGPA is associated with AVTE in approximately one quarter of patients, particularly around diagnosis. Immunosuppressants seemed to exert a protective effect, while anticoagulant and antiplatelet agents did not.Competing Interest StatementDr. Silvia Tamanini worked at ASST Spedali Civili Brescia, Unit of Rheumatology and Immu-nology at the moment of the study. At the moment of publication, she works at Glaxo Smith Kline. All other authors report no conflicts of interest.Clinical TrialThis is a retrospective observational studyFunding StatementThis study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in compliance with the Declaration of Helsinki and approved by the Ethic Committee of the University Hospital Careggi, Florence, Italy (Approval number 12804/CAM_BIO).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified participant data are available upon reasonable request, to be sent by email to the corresponding author.}, URL = {https://www.medrxiv.org/content/early/2021/01/06/2020.11.09.20228197}, eprint = {https://www.medrxiv.org/content/early/2021/01/06/2020.11.09.20228197.full.pdf}, journal = {medRxiv} }